À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, Á¦Çüº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Floating, Expandable), By Dosage (Tablets, Capsule, Gel, Liquid), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1587526
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,299,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,694,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,484,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö 6.4%ÀÇ CAGRÀ» ±â·ÏÇÏ¿© 2030³â±îÁö 227¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ÒÈ­°ü È®ÀåÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ(DDS)Àº Èí¼ö°¡ »óºÎ ¼ÒÈ­°ü(GIT)¿¡ ±¹ÇѵǾî È¿À²ÀûÀ¸·Î Àü´ÞµÉ ¼ö Àֱ⠶§¹®¿¡ »ýü ÀÌ¿ë·üÀÌ ³·Àº ¾à¹°¿¡ ÀÌÁ¡À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Àý´ëÀûÀÎ »ýü ÀÌ¿ë·üÀ» ³ôÀ̰í Èí¼ö¸¦ ±Ø´ëÈ­ÇÏ´Â °ÍÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ DDSÀÇ ¸î °¡Áö ÀåÁ¡Àº Ä¡·á È¿À²°ú ¾à¹°ÀÇ »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃŰ´Â °ÍÀÔ´Ï´Ù. ÅëÁ¦µÇ°í ü°èÀûÀÎ DDS´Â Áúº´ ºÎÀ§¿¡¼­ ¾à¹°ÀÌ °úµµÇÏ°Ô ³ëÃâµÉ °¡´É¼ºÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ Ã¼³» ¾à¹° ´ë»ç°¡ ¾ïÁ¦µÇ¾î ´õ ³ôÀº Ä¡·á È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ À§³» ü·ù¼º DDS¿Í °ü·ÃµÈ ´Ù¾çÇÑ ÀÌÁ¡ÀÌ Àüü ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

DDS´Â ¾à¹°ÀÇ ¹æÃâÀ» À¯ÁöÇÏ¿© ¼ÒÀå°ú À§Àå¿¡¼­ ±¹¼Ò Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ¹æ¹ýÀº ¼ÒÀå°ú À§Àå°ú °ü·ÃµÈ ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ À¯¿ëÇÕ´Ï´Ù. À§ ¹× ¼ÒÀå °ü·Ã ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ È¿À²ÀûÀÎ DDS¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³»½Ã°æ ¼¾ÅÍ¿¡ µû¸£¸é ¸Å³â ¾à 6,200¸¸ ¸íÀÌ ¼ÒÈ­±â ÁúȯÀ¸·Î Áø´Ü¹Þ°í ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ¼ÒÈ­±â ÁúȯÀÇ À¯º´·üÀº ¿¬·É¿¡ µû¶ó Áõ°¡ÇÏ¿© ¼ºÀΰú ³ë³âÃþ¿¡ ´ëÇÑ »õ·Î¿î ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ DDS´Â À§ Á¡¸·ÇÏ Á¶Á÷¿¡ ±í¼÷ÀÌ ¹¯Çô ÀÖ´Â Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±ÕÀ» Á¦°ÅÇÏ¿© ½Äµµ¿°À» Æ÷ÇÔÇÑ ½ÊÀÌÁöÀå ±Ë¾ç°ú À§±Ë¾ç Ä¡·á¿¡ È¿°úÀûÀÔ´Ï´Ù. À̿ʹ º°µµ·Î GRDDS´Â À§Àå¿¡¼­ õõÈ÷ ¾à¹°À» ¹æÃâÇÏ¿© Àü½Å ¼øÈ¯¿¡¼­ À¯È¿ ³óµµ¸¦ ¿À·§µ¿¾È À¯ÁöÇÕ´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå È®´ë°¡ ¿¹»óµË´Ï´Ù.

À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çüº° ºñÁî´Ï½º ºÐ¼®

Á¦5Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Á¦Çüº° ºñÁî´Ï½º ºÐ¼®

Á¦6Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Åë ä³Îº° ºñÁî´Ï½º ºÐ¼®

Á¦7Àå À§Ã¼·ù ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çü, Á¦Çü, À¯Åë ä³Îº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Gastroretentive Drug Delivery Systems Market Growth & Trends:

The global gastroretentive drug delivery systems market size is expected to reach USD 22.7 billion by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently. Hence enhancing absolute bioavailability and maximizing its absorption is expected to boost market growth during the forecast period.

Several advantages of these DDSs include curative efficiency and an increase in the bioavailability of drugs. The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site. It also offers higher efficiency owing to reduced counter activity by the body. Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.

The DDS sustains the release of drugs and avails local therapy in the small intestine and stomach. The method is useful in the treatment of various disorders related to the small intestine and stomach. Rising cases of stomach and small intestine-related disorders are anticipated to foster the demand for such efficient DDSs. According to the Endoscopy Center, each year around 62.0 million people are diagnosed with digestive disorders. The prevalence of most digestive disorders increases with age, creating demand for novel healthcare systems among adults and the geriatric population.

These DDSs are effective in treating duodenal and gastric ulcers, including esophagitis, by eliminating deeply buried helicobacter pylori from the submucosal tissue of the stomach. Apart from this, GRDDSs release the medicine slowly in the stomach and preserve its effective concentration in systemic circulation for a prolonged period of time. Hence, the above-mentioned factors are predicted to augment market expansion.

Gastroretentive Drug Delivery Systems Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Gastroretentive Drug Delivery Systems Market Variables, Trends, & Scope

Chapter 4. Gastroretentive Drug Delivery Systems Market: Type Business Analysis

Chapter 5. Gastroretentive Drug Delivery Systems Market: Dosage Business Analysis

Chapter 6. Gastroretentive Drug Delivery Systems Market: Distribution Channel Business Analysis

Chapter 7. Gastroretentive Drug Delivery Systems Market: Regional Estimates & Trend Analysis by Type, Dosage, and Distribution Channel

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â